Tours, France and California, USA (January 17, 2022) – TSC Endovision, a pioneer in single-use endoscopy and part of TSC Group, and Flexicare, a leading manufacturer and supplier of medical devices, announce today an exclusive partnership for the distribution of TSC Endovision’s Broncoflex, an innovative single-use bronchoscope, in the US market. 

 The endoscopy market landscape continues to evolve as regulatory bodies across the globe recommend single-use technology to reduce cross-contamination risk and improve patient outcomes. The latest version of the Broncoflex product range was commercially launched in European markets in 2020. The Broncoflex solution is a fully sterile, cost-effective, ergonomically designed solution, requiring only two sizes that cover all flexible bronchoscopy therapeutic indications. The Parties are thrilled to now also make this innovative technology available to US healthcare providers. 

 From Luc Van Schil, CEO and founder of TSC, “We are pleased to announce an exclusive partnership with Flexicare for the US market. This collaboration brings together leading-edge endoscopy technology with a high-performing and experienced commercial US organization. This will allow for a promising Broncoflex US market introduction and will support healthcare’s transition to single-use endoscopy.” 

 With over 2.5 million bronchoscopy procedures performed each year in the US, TSC Endovision and Flexicare are well positioned to bring the Broncoflex to the largest endoscopy market and support acute care physicians with a single-use technology that will meet their flexible bronchoscopy needs. 

 “The addition of the Broncoflex technology to the Flexicare portfolio further supports our commitment to bring innovative, high-quality technologies that meet and exceed the needs of healthcare professionals and improve patient outcomes. We are proud to partner with TSC Endovision in bringing this next level technology to the US market,” states Ghassem Poormand, CEO and founder of Flexicare. 

 About TSC Endovision TSC Endovision has been developing ergonomically designed, single-use flexible endoscopes for more than 10 years and the Broncoflex is currently sold in over 30 countries worldwide. The company’s ambition is to provide easy-to-use solutions adapted to the needs of health care professionals for the benefit of patients. TSC Endovision is part of The Surgical Company (TSC) Group, which is a privately owned Medtech group employing around 500 people and headquartered in The Netherlands with operations in France, Benelux, Germany and the UK. 

It’s only 1st of December but we get to unwrap our presents early this year!

We are pleased to announce that our European operations are now fully re-branded into the Flexicare family.

Since the acquisition of Medisize in late 2017 we have worked diligently to integrate the business into our global operations. This included the transition of production requirements to our in-house facilities and the development of the product portfolio to a focus on our propriety product range with its reputation for innovation, quality, value and service.

COVID-19 | 19th March 2020

Dear Valued Customer,

With the continued spread of the COVID-19, the World Health Organisation (WHO) has now classified the virus as a pandemic. As a global manufacturer and supplier of medical devices, we have received several requests for further information on our Breathing System Filter range.

Flexicare’s range of ThermoShield and VentiShield Breathing Filters protect patients and provides an effective barrier that reduces the transmission of bacteria and viruses between respiratory equipment and the environment.

Flexicare’s Breathing System Filters have been tested for Sodium Chloride filtration efficiency by an ISO 17025 accredited third party laboratory in accordance with BS EN ISO 23328:2008 – Breathing System Filters for anaesthetic and respiratory use – Part one: Salt Test method to assess filtration performance. Testing was performed in compliance with US FDA good manufacturing practice (GMP) regulations 21 CFR Parts 210, 211 and 820.

This procedure was performed to evaluate the filtration performance of BSF. The testing was performed to comply with BS EN ISO 23328-1 (2008). The BSF was tested in the unused state as removed from the packaging and after conditioning which stimulates clinical use. Conditioning of the BSF was performed by exposing the filter to one of various positions on a conditioning apparatus prior to filtration efficiency testing.

A neutralised poly-dispersed aerosol of sodium chloride (NaCl) was generated and passed through the test article. The performance of the BSF was assessed by measuring the concentration of salt particles penetrating the BSF compared to the challenge concentration entering the BSF. The filtration performance and airflow resistance of each test article were calculated.

All test method acceptance criteria were met. Further information on individual filter performance can be provided by your local Flexicare representative.

Flexicare is awarded the Insider’s Made in Wales 2019 Medical, Life Sciences and Healthcare Awardon it’s 30^th year of operation.

Flexicare Is proud to be celebrating it’s 30^th Anniversary by winning Insider’s Made in Wales 2019 Medical, Life Sciences and Healthcare Award.

Insider‘s Made in Wales event took place at Cardiff City Hall with a host of Wales’ most innovative, sustainable and forward thinking manufacturers.

Flexicare was awarded Medical, Life Sciences and Healthcare Award. This award is for the pharmaceutical, biomedical, biotechnology, health product or medical devices company that the judges deem has had the biggest impact in the region and beyond. Flexicare has boosted sales by 120% in two years and is proud to be recognised as a leading manufacturer on its 30^th year of operation.

www.financeawardswales.com/winners

Flexicare is celebrating its 30^th Anniversary. Established in 1989 this is Flexicare’s 30^th year of operation in the medical device industry.

Flexicare is a leading designer, manufacturer and supplier of medical devices with a focus on anaesthesia, respiratory and urology products. Established in the UK in 1989 Flexicare now sells to over 105 countries internationally and has in-house manufacturing in China, Sri Lanka and the UK.

Flexicare operates from headquarters in Mountain Ash, Wales. With a base in the UK, Flexicare is supported through its subsidiaries, offices and related companies in the US, Netherlands, Germany, Italy, Middle East, India, Sri Lanka, China, Malaysia, South Korea, Japan and Australia. Trading since 1989, Flexicare has experienced significant global growth, both organically and through selective acquisition.

Flexicare continues to deliver year on year growth, reaching new milestones in its 30th year of operation. The momentum that we have gained over the last few years has been as a result of new product introductions, establishing new markets and continued development. Our ideology of producing high quality medical consumables with a focus on exceeding customers’ expectations, has enabled Flexicare to build on its foundations.

Follow us on twitter, instagram, facebook or linkedin to see the full Flexicare journey.

Flexicare celebrates winning Chief Financial Director over £25m of the year award 2019 at the Finance Awards Wales. 

Flexicare is proud to announce that our Finance Director, Marc Davies won the Chief Financial Director up to £25 million award at Finance Awards Wales 2019. He was recognised as a dynamic individual at the core of our finance team leading strong results and inspiring the team.

Finance Awards Wales is designed to recognise and celebrate the finance professionals of Wales. This year held at Cardiff City hall Flexicare was honoured to not only win the Chief Financial Director up to £25 million but also to be nominated for the small finance team of the year award.

www.financeawardswales.com/winners

Flexicare, a leading UK headquartered manufacturer of medical devices, is pleased to announce that it has acquired Medisize B.V. from an affiliate of Phillips-Medisize.

Medisize is a manufacturer specialising in the supply and distribution of a wide range of respiratory and anaesthesia products for critical care, neonatology, emergency, homecare and radiology (Airway Management). The acquisition of Medisize includes operations in the Netherlands, and subsidiaries in Germany and Italy.

This transaction provides Flexicare with an enhanced presence in mainland Europe supported by the Medisize sales and distribution networks in three European geographies. Acquiring Medisize supplements the Flexicare global product portfolio providing greater choice and coverage for existing and new customers.

The sale of Medisize B.V. by Phillips-Medisize will enable both organisations to focus on their differing areas of expertise, thus better serving the needs of their distinct customer groups. The business acquired does not include any of the contract manufacturing and design consultancy businesses of Phillips-Medisize in the Netherlands, Czech Republic or elsewhere.

Commenting on the deal, Flexicare Managing Director Hash Poormand said:

“This transaction underscores our commitment across Europe to be a leader in airway management and anaesthesia, with the ability to deliver and service the market at scale.

The rapid organic growth that we have enjoyed, as a result of our innovative product portfolio and recent acquisitions, will give us further reach and the combination of the two companies will increase the value Flexicare and Medisize B.V. deliver to its customers and end users. The acquisition is expected to immediately accelerate revenue growth and drive overall earnings growth potential for Flexicare’s wider range of anaesthesia and airway management products, truly exciting times ahead.”

Matt Jennings, CEO and President, Phillips-Medisize commented:

“We believe this is a very positive transaction for both Flexicare and Phillips-Medisize. The Airway Management business closely aligns with Flexicare’s vision. Flexicare’s strength and presence in this market makes them well-positioned to fully leverage the talent and expertise of the Airway Management team in continuing to provide innovative airway management solutions.”

Flexicare has a long standing history of working in partnership with clinicians and University Hospitals to develop new, innovative products, and supporting the ongoing education of students and clinicians, helping to create a better future for patients.

This partnership has just taken a major step forward with the launch of The Bill Mapleson Centre, a new State-of-Art Centre for medical training and product testing at Flexicare’s HQ in South Wales.

The Centre is named after the famous Professor Mapleson, who classified breathing systems in his British Journal of Anaesthesia paper in 1954 and went on to have significant achievements related to pharmacokinetics and ventilators.

At a major ceremony on 22nd May, Professor Mapleson was there to celebrate the opening in the presence of dignitaries such as the Health Minister, Mark Drayford, Cardiff University Deputy Vice Chancellor Professor Elizabeth Treasure and Professor Judith Hall from Cardiff University School of Medicine, joined by over 100 guests.

The Bill Mapleson Centre will provide:

State-of-the-Art Laboratory Facilities for equipment development and independent testing in a purpose built physics laboratory.
Medical Training Space with a Clinical Simulation Suite for undergraduate and postgraduate students to develop anaesthesia and intensive care skills using state of the art simulators in a clinical environment.

The Centre will also provide continuous professional development and refresher training to the wider medical community, including General Practitioners and Dentists.

Having supported the first Simulation Centre in Cardiff University, Flexicare are proud to continue this partnership where industry and academia can work together for the benefits of improved patient care.

Image © Mike Hall, 2014

Many hospitals have traditionally used re-usable devices, but are they aware that single patient use could save them money and improve the care of their patients? To explain the benefits, Flexicare has produced a new animated video, illustrating the importance of Single Patient Use devices.

With over 1.7 million hospital acquired infections per year¹ in the US alone, it’s important to raise awareness of single patient use medical devices, helping clinicians eliminate cross-infection and reduce risk. The video poses challenging questions and presents statistics regarding the benefits of using single patient use devices to enhance patient safety, in a fun and imaginative way.

According to the AAGBI, “Where appropriate, single-use disposable equipment will remove the difficulties of re-use and decontamination procedures. The use of such equipment is to be encouraged.”²

Flexicare offers a wide range of single patient use devices, including BritePro Solo, LarySeal, Anaesthesia Face Masks, ET Tubes, Breathing Systems, and much more.

Why not subscribe to the Flexicare YouTube Channel? You can access the video library more quickly and easily, and get a notification every time new material is added.

¹ Klevens R, Edwards J. Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002. CDC Public Health Reports. 2007 Mar–Apr;(122):160–166.

² Anaesthesia 2008, 63; 1027-36.